The Latest Breaking News from Stryker

Summary Stryker Corporation (SYK) shows strong technical buy signals, with a 6.09% gain since 8/21, and consistent price appreciation across key moving averages. The company operates in MedSurg, Neurotechnology, Orthopaedics, and Spine segments, offering a wide range of medical devices and technologies. Analysts provide mixed ratings, with price targets ranging...

Despite Stryker’s outperformance relative to the healthcare sector over the past year, Wall Street analysts remain cautiously optimistic about the stock’s prospects.

Stryker has recently underperformed the Dow Jones, but Wall Street analysts anticipate a moderate upside for the stock.

A Relative Strength Rating upgrade for Stryker shows improving technical performance. Will it continue?

Stryker sees its Relative Strength Rating reach the 80-plus level.

Shares of Stryker, Boston Scientific jumped early Wednesday after healthy earnings beats and price target hikes from analysts.

With rapidly increasing healthcare demands, numerous technological breakthroughs, and advanced research and development, the medical industry is well-poised for remarkable growth and profitability. As medical companies Danaher (DHR) and Stryker (SYK) gear to report their fourth-quarter earnings tomorrow, let’s determine if these stocks are ideal buys ahead of earnings….

Stryker stock tumbled Friday after sales of its hip and knee replacements came up short, stoking worries of pressure from weight-loss drugs.

The market rally held up, for now, amid a Fed forecast of two more rate hikes. Tesla ended a big win streak. Medical product firms flashed buy signals.